Company Overview and News
Hong Kong’s main Hang Seng index rose to a more than one-week high by lunch break on Monday, as strength in overseas markets provided support, with banks and financial stocks leading the charge, while China's H-shares index climbed to an over two-week high.
MSCI will include onshore “A shares” in its MSCI China Index this year. So what kind of market is it?
China stocks rose on Monday morning to new two-year highs, helped by gains in the defensive consumer and healthcare firms as well as a boost from tech shares.
Shares of the cement maker tumbles most since August 2015 in Shanghai and Hong Kong after clinker prices fell by 30pc in eastern China
China shares rose early Wednesday, led by banking and consumer stocks, and were on track to climb for a ninth straight session.
China shares on Tuesday were trying to extend a rally to an eighth straight day and were up at midday, helped by gains for consumer and healthcare firms. At 04:03 GMT, the Shanghai Composite index was up 2.76 points or 0.08 per cent at 3,412.24.
UBS analyst says a slowdown in property sales will be offset by growth in industries ranging from steel to cement
The 30-day volatility in the Shanghai Composite Index hit a one-year high this week as investors forecast gains will expand to more stocks
Even a 36 per cent rally in Hong Kong’s Hang Seng Index this year has failed to narrow the price gap of the Chinese companies that trade both in the city and China. The Hang Seng AH Premium Index finished at 129.88 on Thursday, compared with its last close of 122.35 in 2016. That means China-traded shares are now almost 30 per cent more expensive than their Hong Kong-listed counterparts. One reason might be that dual-listed companies are lagging Chinese firms while companies only listed in Hong Kong such as Geely Automobile Holdings and Tencent Holdings are the leading annual gainers on the Hang Seng Index.
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
Analysts see prices rising from the fourth quarter as supply remains constrained. Top maker Anhui Conch’s shares rise over 5 per cent and Huaxin jumps 10 per cent
Jidong Cement is among stocks that have surged by their 10 per cent limit for three straight days after Beijing unveiled plans for Xiongan New Area
The insider activity fell before the Chinese Lunar New Year break with 30 companies that recorded 157 purchases worth HK$303 million versus 14 firms with 50 disposals worth HK$121 million. The buy figures were down from the previous week’s 37 companies, 187 purchases and HK$370 million.
Equity market analysts highlight energy, raw materials, industrials, technology, and health care among themes to watch this Lunar New Year
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...